Evidence map›Paper›PMID 29223954›Full record

SynthesisJournal of the American Heart Association2017

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.

Aris Karatasakis, Barbara A Danek, Judit Karacsonyi, Bavana V Rangan, Michele K Roesle, Thomas Knickelbine, Michael D Miedema, Houman Khalili, Zahid Ahmad, Shuaib Abdullah and 2 more

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03634293 (PCSK9 Inhibitor), which is not on this map. Cited by 86 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03634293 phase2 / phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

PCSK9 Inhibitor: a New Tool to Fight Septic Shock

TypeinterventionalSponsorWolfson Medical CenterRan2019 to 2021Enrolled712ConditionsSepsis, Septic ShockArmsAlirocumab Injectable Product, Saline Solution
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy.International journal of environmental research and public health · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aris KaratasakisVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Barbara A DanekVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Judit KaracsonyiVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Bavana V RanganVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Michele K RoesleVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Thomas KnickelbineMinneapolis Heart Institute, Minneapolis, MN.
Michael D MiedemaMinneapolis Heart Institute, Minneapolis, MN.
Houman KhaliliVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Zahid AhmadVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Shuaib AbdullahVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Subhash BanerjeeVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX.
Emmanouil S BrilakisVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, TX esbrilakis@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. METHODS AND

resultsWe performed a systematic review and meta-analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow-up: 85.5 weeks) were included. Mean age was 61.0±2.8 years, and mean baseline low-density lipoprotein cholesterol was 106±22 mg/dL. Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81];

conclusionsTreatment with a PCSK9 inhibitor is well tolerated and improves cardiovascular outcomes. Although no overall benefit was noted in all-cause or cardiovascular mortality, such benefit may be achievable in patients with higher baseline low-density lipoprotein cholesterol.

Indexed as

PCSK9 InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsHumansHypercholesterolemiaProprotein Convertase 9Randomized Controlled Trials as TopicTreatment OutcomealirocumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9alirocumabevolocumabhyperlipidemiaoutcomePCSK9

Identifiers

PMID29223954
PMCPMC5779013

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.